Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Urology Physician in San Francisco, CA
NPI: 1124157474Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Group Business Services
ucsfhealth.org
HQ Phone
Get M.D Sima's Phone Numberphone_androidMobile
Get M.D Sima's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2007 - 2027
TX State Medical License
2012 - 2014
American Board of Urology
Urology
Feinberg School of Medicine
feinberg.northwestern.edu
Medical School
Until 2006
UCSF School of Medicine
medschool.ucsf.edu
Residency • Urology
2008 - 2012
Residency • Surgery
2006 - 2008
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 52000Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | 238 | 478 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 86 | 119 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 85 | 85 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 63 | 75 |
| 5 | 52235Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 36 | 40 |
Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.
Authors: Maxwell Meng
Publication Date: 2017-01-09
Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database.
Authors: Samuel Washington, Maxwell Meng, Peter Lonergan
Publication Date: 2020-07-31
The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
Authors: Badrinath Konety, Ronald Loo
Publication Date: 2021-08-05
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: Canadian Cancer Trials Group
Intervention / Treatment: DRUG: Atezolizumab
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: BCG Tokyo-172 Strain Vaccine, BIOLOGICAL: BCG Solution, BIOLOGICAL: BCG Tokyo-172 Strain Solution
